본문 바로가기 주메뉴 바로가기

제품소개

제품상세페이지

Proteogenix

[Proteogenix] Anti-CoV-RBD (B5) antibody

Cat-No. PTXCOV-A521E


Proteogenix는 Primary Antibody Biosimilar - Research Grade 

제품을 전문적으로 생산하는 20년의 경험이 있는 High Quality 제조사입니다.




제품 설명 


Anti-CoV-RBD (B5) antibody

 



제품 번호

 

PTXCOV-A521E

 



제품 특징


Product nameAnti-CoV-RBD (B5) antibody
SpeciesHuman
Expression systemMammalian
Molecular weight150kDa
Purity85%
BufferPBS, pH7,5
FormLiquid
Delivery conditionBlue ice (+4°C)
Storage condition4°C for short term; -20°c or -80°C for long term
BrandProteogenix
ReferencePTXCOV-A521E
NoteFor research use and in vitro diagnostic only. Not suitable for human use.
IsotypeIgG1
ClonalityMonoclonal Antibody
TargetRBD domain- SARS-CoV2 Spike protein


Description of Anti-CoV-RBD (B5) antibody

General information on Anti-CoV-RBD (B5) antibody

The anti-CoV-RBD (B5) antibody targets the RBD (receptor-binding domain) of the new pandemic strain of coronavirus, SARS-CoV-2. Initially detected in December 2019, the new strain continues to spread unattained causing unimaginable losses. Antibodies have been identified as potential game-changers in the development of life-saving therapies for the COVID-19 disease. Moreover, due to their shorter clinical development times in comparison to vaccines, antibodies can also be used to confer temporary immunity to risk groups such as health care workers, elderly, and immunodeficient individuals.
This specific antibody is a fully human IgG molecule with potential SARS-CoV-2 neutralizing activity, confirmed in competition assays using recombinant forms of the RBD and the ACE2 receptor protein (SARS-CoV-2 Surrogate Virus Neutralization Test, sVNT). Its neutralizing activity can be used to reinforce our knowledge regarding the infection mechanisms of SARS-CoV-2, to assess the potential development of spontaneous escape mutants which would result in lower therapeutic efficiencies, and to detect the presence of SARS-CoV-2 in multiple samples.
The fully human antibody’s specificity and binding affinity have been further tested and validated in ELISA plates (enzyme-linked immunosorbent assay) against the recombinant form of RBD. Additionally, the ease of expression and stability was further confirmed by producing milligram amounts of the recombinant antibody (rAb) in the transient CHO-based mammalian system, XtenCHO™.




QC & Validation Data


SDS-PAGE for Anti-CoV-RBD (B5) antibody

Anti-CoV-RBD (B5) antibody, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.




ProteoGenix의 모든 제품들을 만나보세요!

 

Proteogenix - Exclusive Distributor in South Korea "Morebio" 한국 독점 대리점 "모아바이오"